Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 4/20 | 0.56 |
| ▸ | GJB2 | P29033 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 2/20 | 0.49 |
| ▸ | TLR4 | O00206 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.45 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8864499 | 1.00 | IGF2R (0.56) | IGF2RGJB2MAPK1GBA1TLR4 | |
| SCHEMBL8864321 | 1.00 | IGF2R (0.56) | IGF2RGJB2MAPK1GBA1TLR4 | |
| SCHEMBL8691787 | 0.98 | IGF2R (0.55) | IGF2RGJB2MAPK1GBA1TLR4 | |
| SCHEMBL8686568 | 0.98 | IGF2R (0.55) | IGF2RGJB2MAPK1GBA1TLR4 | |
| SCHEMBL8687950 | 0.98 | IGF2R (0.55) | IGF2RGJB2MAPK1GBA1TLR4 | |
| SCHEMBL672020 | 0.93 | IGF2R (0.52) | IGF2RGJB2MAPK1GBA1TLR4 | |
| SCHEMBL28155326 | 0.93 | GJB2 (0.50) | IGF2RGJB2MAPK1GBA1TLR4 | |
| SCHEMBL9287099 | 0.91 | GJB2 (0.48) | IGF2RGJB2MAPK1GBA1TLR4 | |
| SCHEMBL9289614 | 0.91 | GJB2 (0.48) | IGF2RGJB2MAPK1GBA1TLR4 | |
| SCHEMBL7560314 | 0.91 | CETP (0.48) | IGF2RGJB2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107638653-B | Preparation method of water-based fire extinguishing agent | 广东国信融资租赁有限公司 | 2021-05-18 | — | — | CN | claimed |
| US-11684065-B2 | Oil-based suspension concentrates with low gravitational separation and low viscosity | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20230148591-A1 | USE OF OIL BASED SUSPO-EMULSION CONCENTRATES FOR REDUCING DRIFT DURING SPRAY APPLICATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-18 | — | — | US | disclosed |
| EP-3994988-A1 | AGROCHEMICAL COMPOSITION WITH IMPROVED DRIFT, SPREADING AND RAINFASTNESS PROPERTIES | Bayer AG (DE) | 2022-05-11 | — | — | EP | disclosed |
| EP-3994986-A1 | AGROCHEMICAL COMPOSITION WITH IMPROVED DRIFT AND SPREADING PROPERTIES | Bayer Aktiengesellschaft (DE) | 2022-05-11 | — | — | EP | disclosed |
| EP-3994995-A1 | LOW DRIFT, RAINFASTNESS, HIGH SPREADING, HIGH UPTAKE AND ULV TANK MIX ADJUVANT FORMULATION | Bayer Aktiengesellschaft (DE) | 2022-05-11 | — | — | EP | disclosed |
| EP-3994981-A1 | METHOD FOR LOW VOLUME SPRAY APPLICATION | Bayer Aktiengesellschaft (DE) | 2022-05-11 | — | — | EP | disclosed |
| EP-3994990-A1 | AGROCHEMICAL COMPOSITION WITH IMPROVED DRIFT, SPREADING AND UPTAKE PROPERTIES | Bayer AG (DE) | 2022-05-11 | — | — | EP | disclosed |
| EP-3994993-A1 | LOW DRIFT, RAINFASTNESS, HIGH SPREADING AND ULV TANK MIX ADJUVANT FORMULATION | Bayer Aktiengesellschaft (DE) | 2022-05-11 | — | — | EP | disclosed |
| EP-3994991-A1 | AGROCHEMICAL COMPOSITION WITH IMPROVED DRIFT, SPREADING, UPTAKE AND RAINFASTNESS PROPERTIES | Bayer Aktiengesellschaft (DE) | 2022-05-11 | — | — | EP | disclosed |
| WO-2014123916-A1 | A LIQUID NON-IONIC SALT-FREE SKIN AND HAIR TREATMENT COMPOSITION | FORMULA XO, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-7294342-B2 | Ectoparasite asphyxiator compositions and methods for their application | SUMMERS LABORATORIES, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1708569-A4 | METHODS FOR TREATING ECTOPARASITE INFECTIONS ON THE MAMMALIAN BODY | SUMMERS LAB INC (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1708569-A1 | METHODS FOR TREATING ECTOPARASITE INFECTIONS ON THE MAMMALIAN BODY | Summers Laboratories Inc. (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006071248-A1 | METHODS FOR TREATING ECTOPARASITE INFECTIONS ON THE MAMMALIAN BODY | SUMMERS LABORATORIES INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20060140995-A1 | Methods for treating ectoparasite infections on the mammalian body | SHIONOGI IRELAND LIMITED (IE) | 2006-06-29 | — | — | US | disclosed |
| US-6793931-B2 | Killing lice with a benzyl alcohol gel; pesticide-free | SUMMERS LABORATORIES, INC. | 2004-09-21 | — | — | US | disclosed |
| US-20040013700-A1 | Compositions for treating ectoparasite infections and methods for their application | SHIONOGI IRELAND LIMITED (IE) | 2004-01-22 | — | — | US | disclosed |
| US-20040009204-A1 | Ectoparasite asphyxiator compositions and methods for their application | SHIONOGI INC. | 2004-01-15 | — | — | US | disclosed |
| US-20040009203-A1 | Ectoparasite asphyxiator compositions and methods for their application | SHIONOGI INC. | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009203-A1 | Ectoparasite asphyxiator compositions and methods for their application | COXFA4L2, MASTL, CAT | IGF2R 2787/4885GJB2 227/4885MAPK1 4441/4885 |
| US-20040013700-A1 | Compositions for treating ectoparasite infections and methods for their application | DPM1, CUTA, TYR | IGF2R 2369/4885GJB2 908/4885MAPK1 4439/4885 |
| US-20060140995-A1 | Methods for treating ectoparasite infections on the mammalian body | CUTA, MASTL, AGL | IGF2R 1935/4885GJB2 1522/4885MAPK1 3997/4885 |
| US-20040009204-A1 | Ectoparasite asphyxiator compositions and methods for their application | COXFA4L2, MASTL, CAT | IGF2R 2304/4885GJB2 138/4885MAPK1 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.